New model of subconjunctival tumor development in rabbits.

J Biomed Opt

Pukyong National University, Department of Biomedical Engineering/Interdisciplinary Program of Medical Biotechnology Application Engineering, Busan 608-737, Republic of Korea.

Published: July 2013

Conjunctival squamous cell carcinoma (SCC) is an uncommon disease. However, SCC has recently become an important clinical problem due the identification of a significantly high incidence of SCC among a group of black African patients with AIDS. However, basic research concerning SCC, including both intraepithelial and invasive squamous neoplasia, is limited due to the lack of an ocular tumor animal model. Specifically, current ocular imaging and treatment modalities are insufficient for investigating currently available small animal models, because the conjunctival space is not comparable to that of humans. We describe the development of a reproducible model of subconjunctival squamous carcinoma in moderate-sized immunocompetent rabbits. Under optical coherence tomography guidance, 1×10⁷ VX2 carcinoma cells are inoculated into the subconjunctival space of 3 to 4-kg New Zealand white rabbits. Malignant tumor involvement developed on the subconjunctival space after an average of 1 to 2 weeks. This subconjunctival tumor model induction method will likely facilitate a broad range of investigation of subconjunctival cancer diagnostics and therapeutics.

Download full-text PDF

Source
http://dx.doi.org/10.1117/1.JBO.18.7.070501DOI Listing

Publication Analysis

Top Keywords

model subconjunctival
8
subconjunctival tumor
8
subconjunctival space
8
subconjunctival
5
model
4
tumor
4
tumor development
4
development rabbits
4
rabbits conjunctival
4
conjunctival squamous
4

Similar Publications

Purpose: To evaluate the effect of subconjunctival injection of dexpanthenol on corneal neovascularization and inflammation in rats with induced chemical burns.

Methods: This experimental study included 40 female albino Wistar rats. Chemical burns were induced in the right eye of all rats on the first day, and the left eye was used as a control.

View Article and Find Full Text PDF

Subconjunctival fibrosis (SCF) is a common and refractory eye disease that is a serious threat to vision. The severe side effects of existing drugs and low drug bioavailability due to the ocular barrier are major challenges in SCF treatment. Hence, there is an urgent need to explore safer and more effective strategies for administering anti-SCF drugs.

View Article and Find Full Text PDF

Therapeutic Potential of Dimethyl Sulfoxide Subconjunctival Injection in a Diabetic Retinopathy Rat Model.

In Vivo

December 2024

Laboratory of Veterinary Ophthalmology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic for Korea

Background/aim: Diabetic retinopathy (DR), a complication of diabetes, causes damage to retinal blood vessels and can lead to vision impairment. Persistent high blood glucose levels contribute to this damage, and despite ongoing research, effective treatment options for DR remain limited. Dimethyl sulfoxide (DMSO) has shown anti-inflammatory and antioxidant properties in both in vivo and in vitro studies; however, its potential as an anti-inflammatory agent in the context of DR has not yet been explored.

View Article and Find Full Text PDF

Sustained release of RNA nanoparticles from reservoir implant for ocular delivery.

J Pharm Sci

December 2024

Division of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, United States. Electronic address:

Article Synopsis
  • RNA nanoparticles show promise for ocular delivery, particularly for chronic eye diseases, using a periocular reservoir implant like an episcleral implant.
  • The study aimed to create these implants, test their release performance with model substances and RNA nanoparticles, and apply hindered transport theory to analyze the release rates.
  • Findings showed that the release rates depended on both the size of the substances and the implant membrane's characteristics, indicating a potential for extended delivery of RNA nanoparticles through this implantation method.
View Article and Find Full Text PDF

Italian XEN-Glaucoma Treatment Registry (XEN-GTR): Effectiveness and Safety at 36 Months of XEN45 Implant.

J Clin Med

December 2024

Department of Surgical, Medical, Molecular Pathology and of Critical Care Medicine, University of Pisa, Via Savi 10, 56126 Pisa, Italy.

: We evaluated the 3-year effectiveness and safety of XEN45, combined or not with phacoemulsification, in patients from the Italian XEN-Glaucoma Treatment Registry. : Data from glaucoma patients who underwent XEN45 alone or combined with phacoemulsification were analyzed. Changes in intraocular pressure (IOP) and the number of ocular hypotensive medications (OHMs) were tested with repeated measures ANOVA in last observation carried forward (LOCF) and per-protocol (PP) analyses.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!